Nonsurgical Multidisciplinary Approach for Recurrent Hepatocellular Carcinoma After Surgical Resection

References

• Jemal A , BrayF, CenterMM, FrelayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Bosch FX , RibesJ, DíazM, ClériesR. Primary liver cancer: worldwide incidence and trends. Gastroenterology127(5 Suppl. 1), S5–S16 (2004).
   PubMed Web of Science ®Google Scholar
• Forner A , ReigME, de LopeCR, BruixJ. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis.30(1), 61–74 (2010).
   PubMed Web of Science ®Google Scholar
• Bruix J , ShermanM. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology53(3), 1020–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Kudo M , IzumiN, KokudoNet al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis.29(3), 339–364 (2011).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer . EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol.56(4), 908–943 (2012).
   PubMed Web of Science ®Google Scholar
• Imamura H , MatsuyamaY, TanakaEet al. Risk factors contributing to early and late Phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol.38(2), 200–207 (2003).
   PubMed Web of Science ®Google Scholar
• Minagawa M , MakuuchiM, TakayamaT, KokudoN. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann. Surg.238(5), 703–710 (2003).
   PubMed Web of Science ®Google Scholar
• Poon RT , FanST, LoCM, LiuCL, WongJ. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann. Surg.229(2), 216–222 (1999).
   PubMed Web of Science ®Google Scholar
• Chan DL , MorrisDL, ChuaTC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. Surg. Oncol.22(2), e23–e30 (2013).
   PubMed Web of Science ®Google Scholar
• Chan DL , AlzahraniNA, MorrisDL, ChuaTC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J. Gastroenterol. Hepatol.29(1), 31–41 (2014).
   PubMed Web of Science ®Google Scholar
• Poon RT , FanST, O'SuilleabhainCB, WongJ. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J. Am. Coll. Surg.195(3), 311–318 (2002).
   PubMed Web of Science ®Google Scholar
• Choi D , LimHK, RhimHet al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann. Surg. Oncol.14(8), 2319–2329 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PH , LinWJ, TsangYMet al. Clinical management of recurrent hepatocellular carcinoma. Ann. Surg.222(5), 670–676 (1995).
   PubMed Web of Science ®Google Scholar
• Shim JH , KimKM, LeeYJet al. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann. Surg. Oncol.17(3), 869–877 (2010).
   PubMed Web of Science ®Google Scholar
• Peng ZW , ZhangYJ, LiangHH, LinXJ, GuoRP, ChenMS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology262(2), 689–700 (2012).
   PubMed Web of Science ®Google Scholar
• Shimada K , SakamotoY, EsakiMet al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann. Surg. Oncol.14(8), 2337–2347 (2007).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RicciS, MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AL , KangYK, ChenZet al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Kim KM , KimJH, ParkISet al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J. Gastroenterol. Hepatol.24(5), 806–814 (2009).
   PubMed Web of Science ®Google Scholar
• Yoo DJ , KimKM, JinYJet al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J. Gastroenterol. Hepatol. 26(1), 145–154 (2011).
   PubMed Web of Science ®Google Scholar
• Choi GH , ShimJH, KimMJet al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology269(2), 603–611 (2013).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RealMI, MontañaXet al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Hong K , KhwajaA, LiapiE, TorbensonMS, GeorgiadesCS, GeschwindJF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res.12(8), 2563–2567 (2006).
   PubMed Web of Science ®Google Scholar
• Sangro B , D'AvolaD, IñarrairaeguiM, PrietoJ. Transarterial therapies for hepatocellular carcinoma. Expert Opin. Pharmacother.12(7), 1057–1073 (2011).
   PubMed Web of Science ®Google Scholar
• Lammer J , MalagariK, VoglTet al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol.33(1), 41–52 (2010).
   PubMed Web of Science ®Google Scholar
• Sangro B , IñarrairaeguiM, BilbaoJI. Radioembolization for hepatocellular carcinoma. J. Hepatol.56(2), 464–473 (2012).
   PubMed Web of Science ®Google Scholar
• Yoon SM , LimYS, WonHJet al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int. J. Radiat. Oncol. Biol. Phys.82(5), 2004–2011 (2012).
   PubMed Web of Science ®Google Scholar
• Kim SW , OhD, ParkHCet al. Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiat. Oncol. J.32(1), 14–22 (2014).
   PubMedGoogle Scholar
• Tanaka Y , NakazawaT, KomoriSet al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. J. Gastroenterol. Hepatol.29(2), 352–357 (2014).
   PubMed Web of Science ®Google Scholar
• Bruix J , RaoulJL, ShermanMet al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a Phase III trial. J. Hepatol.57(4), 821–829 (2012).
   PubMed Web of Science ®Google Scholar
• Cheng AL , GuanZ, ChenZet al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the Phase III Sorafenib Asia-Pacific trial. Eur. J. Cancer.48(10), 1452–1465 (2012).
   PubMed Web of Science ®Google Scholar
• Chen MS , LiJQ, ZhengYet al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg.243(3), 321e8 (2006).
   Web of Science ®Google Scholar
• Livraghi T , MeloniF, Di StasiMet al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1), 82e9 (2008).
   Web of Science ®Google Scholar
• Raoul JL , SangroB, FornerAet al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev.37(3), 212–220 (2011).
   PubMed Web of Science ®Google Scholar
• Lee HC . Systemic chemotherapy of hepatocellular carcinoma‐‐Korean experience. Oncology75(Suppl.1), 114–118 (2008).
   PubMedGoogle Scholar
• Yeo W , MokTS, ZeeBet al. A randomized Phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst.97(20), 1532–1538 (2005).
   PubMedGoogle Scholar
• Chung YH , SongIH, SongBCet al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer88(9), 1986–1991 (2000).
   PubMed Web of Science ®Google Scholar
• Klein J , DawsonLA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int. J. Radiat. Oncol. Biol. Phys.87(1), 22–32 (2013).
   PubMed Web of Science ®Google Scholar
• Liang SX , ZhuXD, LuHJet al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer103(10), 2181–2188 (2005).
   PubMed Web of Science ®Google Scholar
• Bae SH , ParkHC, Lim doHet al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys.82(4), e603–e607 (2012).
   PubMed Web of Science ®Google Scholar
• Park JH , YoonSM, LimYSet al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. J. Gastroenterol. Hepatol.28(10), 1638–1642 (2013).
   PubMed Web of Science ®Google Scholar
• Price TR , PerkinsSM, SandrasegaranKet al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer118(12), 3191–3198 (2012).
   PubMed Web of Science ®Google Scholar
• Yoon SM , LimYS, ParkMJet al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS ONE8(11), e79854 (2013).
   PubMed Web of Science ®Google Scholar